Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer
Craig Furman, Xiaoling Puyang, Zhaojie Zhang, Zhenhua J Wu, Deepti Banka, Kiran B Aithal, Lee A Albacker, Ming-Hong Hao, Sean Irwin, Amy Kim, Meagan Montesion, Alyssa D Moriarty, Karthikeyan Murugesan, Tuong-Vi Nguyen, Victoria Rimkunas, Tarek Sahmoud, Michael J Wick, Shihua Yao, Xun Zhang, Hao Zeng, Frédéric H Vaillancourt, David M Bolduc, Nicholas Larsen, Guo Zhu Zheng, Sudeep Prajapati, Ping Zhu, Manav Korpal, Craig Furman, Xiaoling Puyang, Zhaojie Zhang, Zhenhua J Wu, Deepti Banka, Kiran B Aithal, Lee A Albacker, Ming-Hong Hao, Sean Irwin, Amy Kim, Meagan Montesion, Alyssa D Moriarty, Karthikeyan Murugesan, Tuong-Vi Nguyen, Victoria Rimkunas, Tarek Sahmoud, Michael J Wick, Shihua Yao, Xun Zhang, Hao Zeng, Frédéric H Vaillancourt, David M Bolduc, Nicholas Larsen, Guo Zhu Zheng, Sudeep Prajapati, Ping Zhu, Manav Korpal
Abstract
Nearly 30% of patients with relapsed breast cancer present activating mutations in estrogen receptor alpha (ERα) that confer partial resistance to existing endocrine-based therapies. We previously reported the development of H3B-5942, a covalent ERα antagonist that engages cysteine-530 (C530) to achieve potency against both wild-type (ERαWT) and mutant ERα (ERαMUT). Anticipating that the emergence of C530 mutations could promote resistance to H3B-5942, we applied structure-based drug design to improve the potency of the core scaffold to further enhance the antagonistic activity in addition to covalent engagement. This effort led to the development of the clinical candidate H3B-6545, a covalent antagonist that is potent against both ERαWT/MUT, and maintains potency even in the context of ERα C530 mutations. H3B-6545 demonstrates significant activity and superiority over standard-of-care fulvestrant across a panel of ERαWT and ERαMUT palbociclib sensitive and resistant models. In summary, the compelling preclinical activity of H3B-6545 supports its further development for the potential treatment of endocrine therapy-resistant ERα+ breast cancer harboring wild-type or mutant ESR1, as demonstrated by the ongoing clinical trials (NCT03250676, NCT04568902, NCT04288089).
Summary: H3B-6545 is an ERα covalent antagonist that exhibits encouraging preclinical activity against CDK4/6i naïve and resistant ERαWT and ERαMUT tumors.
©2022 The Authors; Published by the American Association for Cancer Research.
Figures
References
- Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, et al. . Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep 2013;4:1116–30.
- Robinson DR, Wu Y-M, Vats P, Su F, Lonigro RJ, Cao X, et al. . Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet 2013;45:1446–51.
- Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, et al. . ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 2013;45:1439–45.
- Joseph JD, Darimont B, Zhou W, Arrazate A, Young A, Ingalla E, et al. . The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer. eLife 2016;5:e15828.
- Weir HM, Bradbury RH, Lawson M, Rabow AA, Buttar D, Callis RJ, et al. . AZD9496: an oral estrogen receptor inhibitor that blocks the growth of ER-positive and ESR1-mutant breast tumors in preclinical models. Cancer Res 2016;76:3307–18.
- Bihani T, Patel HK, Arlt H, Tao N, Jiang H, Brown JL, et al. . Elacestrant (RAD1901), a selective estrogen receptor degrader (SERD), has antitumor activity in multiple ER(+) breast cancer patient-derived xenograft models. Clin Cancer Res 2017;23:4793–804.
- Guan J, Zhou W, Hafner M, Blake RA, Chalouni C, Chen IP, et al. . Therapeutic ligands antagonize estrogen receptor function by impairing its mobility. Cell 2019;178:949–63.
- El-Ahmad Y, Tabart M, Halley F, Certal V, Thompson F, Filoche-Romme B, et al. . Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8, 9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a potent and selective estrogen receptor degrader (SERD) for the treatment of estrogen-receptor-positive breast cancer. J Med Chem 2020;63:512–28.
- Kaklamani V, Bardia A, Wilks S, Weise A, Richards D, Harb W, et al. . Final analysis of phase 1 study of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. Cancer Res 2020;80:PD7-07.
- Lim E, Jhaveri K, Perez Fidalgo JA, Bellet M, Boni V, Perez Garcia JM, et al. . A phase 1B study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer. J Clin Oncol 38:15s, 2020. (suppl; abstr 1023).
- Linden HM, Campone M, Bardia A, Ulaner GA, Gosselin A, Doroumian S, et al. . A phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), as monotherapy and in combination with other anti-cancer therapies in postmenopausal women with ER-positive (ER+) /human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (mBC): AMEERA-1; 2020.
- Baird R, Oliveira M, Ciruelos EM, Patel MR, Benejo de las Heras B, Ruiz-Borrego M, et al. . Updated data from SERNA-1: a phase 1 dose escalation and expansion study of the next generation oral SERD AZD9833 as a monotherapy and in combinatin with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer; 2020.
- Puyang X, Furman C, Zheng GZ, Wu ZJ, Banka D, Aithal K, et al. . Discovery of selective estrogen receptor covalent antagonists for the treatment of ERalpha(WT) and ERalpha(MUT) breast cancer. Cancer Discov 2018;8:1176–93.
- Bock M, Hao M-H, Korpal M, Nyavanandi VK, Puyang X, Samajdar S, et al. . Tetrasubstituted alkene compounds and their use. United States: Eisai R&D Management Co., LTD., Tokyo (JP); 2017.
- Bock M, Hao M-H, Korpal M, Nyavanandi VK, Puyang X, Samajdar S, et al. . Tetrasubsitituted alkene compounds and their use. United States: Eisai R&D Management Col, LTD., Tokyo (JP); 2018.
- Coser KR, Chesnes J, Hur J, Ray S, Isselbacher KJ, Shioda T. Global analysis of ligand sensitivity of estrogen inducible and suppressible genes in MCF7/BUS breast cancer cells by DNA microarray. Proc Natl Acad Sci U S A 2003;100:13994–9.
- Norman RA, Schott A-K, Andrews DM, Breed J, Foote KM, Garner AP, et al. . Protein-ligand crystal structures can guide the design of selective inhibitors of the FGFR tyrosine kinase. J Med Chem 2012;55:5003–12.
- Vagin A, Teplyakov A. Molecular replacement with MOLREP. Acta Crystallogr D Biol Crystallogr 2010;66:22–25.
- Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 1997;53:240–55.
- Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol 2016;34:525–7.
- Robinson MD, Mccarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010;26:139–40.
- Law CW, Chen Y, Shi W, Smyth GK. voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol 2014;15:R29.
- Reese JC, Katzenellenbogen BS. Mutagenesis of cysteines in the hormone binding domain of the human estrogen receptor. Alterations in binding and transcriptional activation by covalently and reversibly attaching ligands. J Biol Chem 1991;266:10880–7.
- Furman C, Hao M-H, Prajapati S, Reynolds D, Rimkunas V, Zheng GZ, et al. . Estrogen receptor covalent antagonists: the best is yet to come. Cancer Res 2019;79:1740–5.
- Ekena K, Weis KE, Katzenellenbogen JA, Katzenellenbogen BS. Different residues of the human estrogen receptor are involved in the recognition of structurally diverse estrogens and antiestrogens. J Biol Chem 1997;272:5069–75.
- Brzozowski AM, Pike ACW, Dauter Z, Hubbard RE, Bonn T, Engström O, et al. . Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997;389:753–8.
- Chung JH, Pavlick D, Hartmaier R, Schrock AB, Young L, Forcier B, et al. . Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer. Ann Oncol 2017;28:2866–73.
- Wardell SE, Nelson ER, Chao CA, Mcdonnell DP. Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease. Clin Cancer Res 2013;19:2420–31.
- Toy W, Carlson K, Martin T, Razavi P, Berger M, Baselga J, et al. . Non-canonical, clinical ESR1 mutations promote resistance to antiestrogen therapies. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-04-11.
- Hamilton EP, Wang JS, Pluard TJ, Johnston SRD, Morikawa A, Claire Dees E, et al. . Phase I/II trial of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. J Clin Oncol 39:15s, 2021. (suppl; abstr 1018).
- Korpal M, Furman C, Puyang X, Zhang Z, Wu Z, Banka D, et al. . Development of H3B-6545, a first-in-class oral selective ER covalent antagonist (SERCA), for the treatment of ERaWT and ERaMUT breast cancer; 2020.
- Hamilton EP, Wang JS, Pluard T, Johnston SRD, Morikawa A, Dees EC, et al. . Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer. J Clin Oncol 39:15s, 2021. (suppl; abstr 1018).
- Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006;21:1215–23.
Source: PubMed